Company: ZVRA
Filing Date: 2025-04-24
Form Type: PRRN14A
Source: 0000897069-25-000871
Chunk: 16

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-04-24
Form: PRRN14A
Chunk 16
---
 to vote for the election to the Board of Directors of two highly qualified nominees - Travis C. Mickle, Ph.D. and Arthur C. Regan.If elected as a director of the Company, Mr. Regan would be, an “independent director” within the meaning of (i) applicable Nasdaq listing standards applicable to board composition and (ii) Section 301 of the Sarbanes-Oxley Act of 2002. If elected as a director of the of the Company, Dr. Mickle would not qualify as an “independent director” within the above meaning by virtue of his having been an employee of the Company within the last three years. The Proponent is not seeking to acquire control of the Company. However, if elected, the Nominees, together with the Proponent’s three nominees who were elected at the 2023 annual meeting, will constitute a majority on the Board and will potentially be able to implement any actions that they may believe are necessary to unlock stockholder value. That said none of the Nominees nor any of the prior three nominees is a party to any agreement, arrangement or understanding with, and none has given any commitment or assurance to each other or any other person as to how she or he, will act or vote on any issue or question. Each such person will fulfill its fiduciary duty in determining how to vote on any issue that comes before the Board of Directors. The Proponent’s sole interest is in electing a board with the qualifications and ability to facilitate necessary and meaningful changes in order to maximize long-term value for the Company’s stockholders. Biographical Information Regarding the Nominees The following information concerning the age, principal occupation and business experience during the last five years, and current public directorships of each of the Nominees. Travis C. Mickle, PhD, 52, currently serves as a Senior Advisor and Consultant, providing strategic guidance on FDA interactions, regulatory filings, drug development, and business transactions for pharmaceutical and biotechnology companies. Since 2022, he has consulted for organizations including Zevra, Corium, and Sydnexis, advising on regulatory approvals, investment strategies, and corporate structuring. Previously, Dr. Mickle served as President and Chief Executive Officer of Zevra from 2010 until 2023, where he led the company’s transition from a development-stage to a commercial-stage entity, securing multiple business partnerships and raising over $500 million in equity and debt financing. Dr. Mickle resigned as